echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > BMC Gastroenterology: The effect of the interaction between obesity and high uric acidemia on the severity of non-alcoholic fatty liver disease

    BMC Gastroenterology: The effect of the interaction between obesity and high uric acidemia on the severity of non-alcoholic fatty liver disease

    • Last Update: 2021-02-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Non-alcoholic fatty liver disease (NAFLD) is the fastest growing chronic liver disease, epidemiological data show that the current global prevalence of NAFLD is 25%, and now China is in the rapid development of NAFLD, the national prevalence rate as high as 29.2%.
    , NAFLD increases the risk of cirrhosis and hepatocellular carcinoma.
    in the U.S., direct medical costs are about $103 billion ($1,613 per patient) a year, and in Europe they cost 35 billion euros (from 354 euros to 1,163 euros per patient).
    NAFLD is closely related to metabolic syndrome and related conditions, including obesity, type 2 diabetes, dyslipidemia, hypertension and hyperureticemia.
    previous studies have shown an independent link between high uric acidemia and the severity of liver damage in NAFLD.
    therefore, the purpose of this study is to explore whether obesity can alter the relationship between serum uric acid and the severity of liver damage in NAFLD, as well as the possible interaction between high uric acidemia and obesity.
    researchers conducted cross-sectional studies of a total of 557 ultrasound-diagnosed NAFLDs.
    the degree of liver fatty degeneration and liver fibrosis with transient elastic imaging.
    high uric acidemia is defined as serum uric acid in men, 420 smol/L in women, and obesity as body mass index ≥25 kg/m2.
    the OR values of adjusted high uric acidemia and obesity through multiple logistic regression analysis, and used the addition model to study possible interactions.
    multi-regression analysis showed that high uric acidemia was associated with severe liver fat degeneration (1.74 (1.09-2.79)) and ALT elevation (2.17 (1.38-3.41)) and not with late fibrosis (1.61 (0.91-2.85).
    same time, the researchers found that in obese NAFLD alone, high uric acidemia was associated with a higher risk of severe liver fat degeneration (2.02 (1.14-3.57)) and elevated ALT (2.27 (1.37-3.76)), as was not the case in non-obese subjects.
    same time, people with high uric acidemia are more likely to develop fibrosis in obese people (2.17 (1.13-4.18) than non-obese people (0.60 (0.14-2.70) are not.
    addition, there is an interaction between high uric acidemia and obesity in the likelihood of severe liver fat degeneration (AP: 0.39 (0.01-0.77)) and late fibrosis.
    study confirms that high uric acidemia and obesity have significant synergies between liver fat degeneration and fibrosis.
    , treatment for uric acid may be needed in obese NAFLD.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.